TLR7 agonist JNJ-64794964

An orally bioavailable Toll-like receptor (TLR) 7 agonist, with potential immunostimulating, antiviral and antitumor activities. Upon oral administration, TLR7 agonist JNJ-64794964 specifically targets, binds to and activates TLR7. This triggers anti-viral and anti-tumor activities through the activation of cluster of differentiation (CD) 8-positive T cells, B cells, and innate immune cells including natural killer (NK) cells and macrophages, secretion of interferon alpha (IFNa), and the production of various pro-inflammatory and anti-inflammatory cytokines. TLR7 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate immunity.